Company intelligence / Profile preview

SentientLight

Hayden, Idaho, United States

Ownership: Private
Development stage: Other

Overview

A 10-patient open-label pilot study demonstrated a 20% reduction in pain, 17% decrease in stiffness, and improved joint mobility in early-stage knee osteoarthritis over 12 weeks using SentientLight's PEMF device. The technology is investigational and not FDA cleared, with further trials, including a placebo-controlled insomnia study, planned.[2]

Therapeutic areas: NephrologyImmunologyRheumatologyInfectious DiseasesNeurologyPsychiatry
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on SentientLight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SentientLight.

Explore the full profile